Cat. No.: HY-145584

Nesuparib

(Synonyms: JPI-547/OCN-201)

고객리뷰

Based on 1 Customer Validation

Nesuparib (JPI-547) is the orally active inhibitor for PARP 1/2 and Tankyrase 1/2 that inhibits tankyrases 1, tankyrases 2, and PARP 1 with IC₅₀s of 5, 1 and 2 nM, respectively. Nesuparib exhibits antitumor activity and can be used in research of advanced solid tumor.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.54%
CAS No.: 2055357-64-5
화학식: C₂₃H₂₄N₆O
분자량:400.48

보관:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Nesuparib Chemical Structure

CAS No.: 2055357-64-5

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
용액&용해도
- In Vitro
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target^[2]

tankyrase-2

1 nM (IC₅₀)

PARP2

2 nM (IC₅₀)

tankyrase-1

5 nM (IC₅₀)

All PARP Isoforms :

All Wnt Isoforms :

In Vitro

Nesuparib inhibits the activities of tankyrases, stabilizes AXIN protein, affects its downstream signaling pathways (WNT/β-catenin and Hippo signaling pathway), exhibiting antitumor effect^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Nesuparib exhibits antitumor activity against Olaparib (HY-10162)-resistant breast and ovary cancer in mouse BT474 or SNU251 xenograft models^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 2055357-64-5
Appearance Solid
분자량 400.48
화학식 C₂₃H₂₄N₆O
Color White to off-white
SMILES

N#CC1=CN=C(N2CCN(CC2)CC3=CC(NC(C4=C5NCCC4)=O)=C5C=C3)C=C1
Synonyms

JPI-547/OCN-201
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

용액&용해도

In Vitro:

DMSO : 60 mg/mL (149.82 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4970 mL

12.4850 mL

24.9700 mL

5 mM

0.4994 mL

2.4970 mL

4.9940 mL

10 mM

0.2497 mL

1.2485 mL

2.4970 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same. Patent WO2016200101A2.

[2]. Im S A , et al.A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.[J].Journal of Clinical Oncology, 2021, 39(15_suppl):3113-3113.

[3]. Oh K S, et al. JPI-547, a dual inhibitor of PARP/Tankyrase, shows promising antitumor activity against pancreatic cancers with homologous recombination repair deficiency or Wnt-addiction[J]. Cancer Research, 2023, 83(7_Supplement): 4496-4496.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4970 mL	12.4850 mL	24.9700 mL	62.4251 mL
	5 mM	0.4994 mL	2.4970 mL	4.9940 mL	12.4850 mL
	10 mM	0.2497 mL	1.2485 mL	2.4970 mL	6.2425 mL
	15 mM	0.1665 mL	0.8323 mL	1.6647 mL	4.1617 mL
	20 mM	0.1249 mL	0.6243 mL	1.2485 mL	3.1213 mL
	25 mM	0.0999 mL	0.4994 mL	0.9988 mL	2.4970 mL
	30 mM	0.0832 mL	0.4162 mL	0.8323 mL	2.0808 mL
	40 mM	0.0624 mL	0.3121 mL	0.6243 mL	1.5606 mL
	50 mM	0.0499 mL	0.2497 mL	0.4994 mL	1.2485 mL
	60 mM	0.0416 mL	0.2081 mL	0.4162 mL	1.0404 mL
	80 mM	0.0312 mL	0.1561 mL	0.3121 mL	0.7803 mL
	100 mM	0.0250 mL	0.1249 mL	0.2497 mL	0.6243 mL

Keywords

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Nesuparib

Cytoskeleton Compound Library

Orally Active Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Transcription Factor-Targeted Library

Heterocyclic Compound Library

Extracellular Vesicles (EVs) Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

All PARP Isoforms

All Wnt Isoforms

Biological Activity

Chemical Information

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Nesuparib

Cytoskeleton Compound Library

Orally Active Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Transcription Factor-Targeted Library

Heterocyclic Compound Library

Extracellular Vesicles (EVs) Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

All PARP Isoforms

All Wnt Isoforms

Biological Activity

Chemical Information

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Nesuparib Related Classifications

HY-145584 Related Classifications